Most Read Articles
3 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
14 Oct 2018
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
17 hours ago
Concomitant use of psyllium fibres, taken before meals, appears to enhance the cholesterol-lowering effects of statins, according to a recent meta-analysis.
4 days ago
Smoking appears to increase the risk of abdominal aortic aneurysm, particularly among current smokers, reports a recent meta-analysis. The risk appears to taper with a lower number of cigarette sticks smoked per day.

Fostemsavir improves virologic efficacy, immunologic response in HIV-1

Audrey Abella
07 Aug 2018

The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.

Researchers evaluated the randomized cohort of the study population comprising 272 heavily treatment-experienced participants (67 percent treated for >15 years, 75 percent exposed to ≥5 antiretroviral regimens, median age 48 years, 74 percent male) with confirmed viral load of HIV-1 RNA ≥400 copies/mL who were unable to establish a viable antiretroviral background regimen. Participants received either fostemsavir 600 mg twice/day or placebo (n=203 and 69, respectively) for 8 days on top of their failing regimen. After which, all participants received open-label fostemsavir plus optimized background therapy until week 24. [AIDS 2018, abstract THPEB045]

After the first week of treatment, fostemsavir demonstrated superior efficacy over placebo, generating a clinically significant reduction in viral load (adjusted mean log10 HIV-1 RNA, -0.79 vs -0.17 log10 copies/mL, treatment difference, -0.63, 95 percent confidence interval, -0.81 to -0.44; p<0.0001), which was similar across demographic (ie, age, gender, race, geographic region) and baseline disease subgroups (viral load and CD4+ count).

Fostemsavir use also resulted in a median decline in HIV-1 RNA of 1 log10 copies/mL among patients with baseline HIV-1 RNA >1,000 copies/mL at day 8.

Achieving a meaningful reduction in viral load in a span of one week is a promising outcome, noted the researchers, considering the participants’ limited treatment options and drug resistance.

At week 24, more than half of fostemsavir recipients (54 percent) achieved virologic suppression (HIV-1 RNA <40 copies/mL), with similar virologic response rates across all subgroups. However, lower response rates were observed among those who had a high baseline viral load and low baseline CD4+ count (38 percent with ≥100,000 copies/mL and 37 percent with <50 cells/µL, respectively) as opposed to those with low baseline viral load and high baseline CD4+ count (60 percent with <100,000 copies/mL and 63 percent with 50 cells/µL, respectively).

Regarding CD4+ T-cell count, mean increase was similar across all subgroups at week 24, ranging from 74 to 119 cells/µL (mean, 90 cells/µL), except for those with a baseline CD4+ T-cell count of <1,000 cells/µL (mean, 22 cells/µL).

Participants with a low baseline CD4+ count (<20 cells/µL) had an average increase of 97 cells/µL which, according to the researchers, is comparable in magnitude to the mean change in all other baseline CD4+ categories.

Establishing a regimen that could reduce viral load to undetectable levels and improve CD4+ count is important, as high baseline viral load and low CD4+ count increase the risk of developing comorbidities and HIV progression and transmission. [CD4, viral load, and other tests, www.aidsmap.com, accessed 6 August 2018]

These findings underscore the potential of fostemsavir in addressing the issue of antiviral resistance, which remains an unmet need in heavily treatment-experienced patients with HIV. [J Pharm Sci 2013;102:1742-1751; Infect Disord Drug Targets 2011;11:124-133]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The types of bariatric surgery differentially affect the risk of developing acute pancreatitis postoperatively, such that the risk is greater in patients who undergo vertical sleeve gastrectomy vs Roux-en-Y gastric bypass surgery, according to a study. Risk factors include younger age and presence of gallstones.
14 Oct 2018
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
17 hours ago
Concomitant use of psyllium fibres, taken before meals, appears to enhance the cholesterol-lowering effects of statins, according to a recent meta-analysis.
4 days ago
Smoking appears to increase the risk of abdominal aortic aneurysm, particularly among current smokers, reports a recent meta-analysis. The risk appears to taper with a lower number of cigarette sticks smoked per day.